Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AXEL: Axitinib-Avelumab Combination in Recurrent or Metastatic Nasopharyngeal Cancer: a Multicenter Phase 2 Trial

NCT04562441 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT04562441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AXEL: Axitinib-Avelumab Combination in Recurrent or Metastatic Nasopharyngeal Cancer: a Multicenter Phase 2 Trial
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2021
Completion date
November 7, 2024
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic npc